Brief: Kymera Therapeutics Q4 EPS USD -0.97
26/02/2026 12:00
Feb 26 (Reuters) - Kymera Therapeutics Q4 revenue USD 2.871 million vs. IBES estimate USD 15 million. Q4 operating expenses USD 100.766 million Q4 net income USD -86.981 million
Recent news on Kymera Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Kymera Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates
Brief: Kymera Therapeutics Q2 EPS USD -0.62
Brief: Kymera Therapeutics Appoints Terence Rooney, MD, As Chief Medical Officer